<DOC>
	<DOCNO>NCT00686985</DOCNO>
	<brief_summary>Phase II study docetaxel first line - second line treatment SCLC demonstrate docetaxel active agent patient group . Therefore docetaxel seem suitable evaluation combination cytotoxic drug active disease . A phase II study previously untreated patient SCLC show combination docetaxel cisplatin/carboplatin active well tolerate regimen extensive SCLC .</brief_summary>
	<brief_title>Docetaxel - Carboplatin Second Line Treatment Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>Background : Small cell lung cancer ( SCLC ) diagnose approximately 15 % lung cancer case . SCLC recognize rapid tumor growth , high chemo- radio sensitivity , high metastasize potential . Patients extensive-stage disease 5-year survival rate 1 % 2 % . Almost 2/3 patient already extensive disease ( ED ) upon diagnosis.The recommend treatment ED-SCLC systemic chemotherapy , consider standard first line treatment option patient SCLC regardless performance status age . World-wide , commonly use regimen 1st line treatment combination cisplatin-etoposide , Netherlands cyclophosphamide , doxorubicin etoposide regimen widely used.Survival outcome regimen appear similar . Unfortunately , relapse occur patient responses second-line chemotherapy prove short term . Until recently , register drug treatment relapse SCLC . Phase II study docetaxel first line - second line treatment SCLC demonstrate docetaxel active agent patient group . Therefore docetaxel seem suitable evaluation combination cytotoxic drug active disease . Until study perform combination docetaxel platinum group previously treat SCLC patient . A phase II study previously untreated patient SCLC show combination docetaxel cisplatin/carboplatin active well tolerate regimen extensive SCLC . Study objectives : To evaluate anti-tumor activity docetaxel/carboplatin regimen patient refractory relapse SCLC . Furthermore asses safety profile docetaxel/carboplatin combination . Trial design : This study open label non-randomized study conduct patient refractory relapse SCLC . It phase II study 50 patient . Docetaxel infusion 75 mg/m2 , carboplatin AUC = 6 mg/ml·min day 1 , every 21 day 4-6 cycle . Population : Patients histologically cytologically proven SCLC first diagnosis refractory relapse SCLC first line treatment . Signed informed consent . Age &gt; 18 year . WHO ps 0,1 2 . Endpoints : Primary endpoint : response rate . Secondary endpoint ( ) : time progression , response duration , safety profile survival . Stress risks patient : Hospital visit test different standard treatment . Stress due adverse event essential high estimate . Special risk expect . Frequently medical examination control laboratory result do . Detailed instruction give case serious toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically proven SCLC first diagnosis Refractory relapse SCLC Measurable disease accord RECIST criterion There must minimum 2 week end prior radiotherapy study entry . ( No 30 % available bone marrow irradiate recommend RTOG ) . Patients must fully recover toxic effect previous antitumor therapy . Age &gt; 18 year . WHO performance status 0 2 ( Appendix II ) . Hb &gt; 6.0 mmol/L , Neutrophils &gt; 1.5 x 109/L , Platelets &gt; 100 x 109/L· Total bilirubin &lt; uppernormal limit institutional normal value . ALAT ( SGPT ) , ASAT ( SGOT ) &lt; 2.5 time uppernormal limit institutional normal value . Alkaline Phosphatase &lt; 5 time uppernormal limit institutional normal value . If AP &gt; 2.5 x ULN ALAT ASAT must &lt; 1.5 x ULN , otherwise , patient eligible Creatinine &lt; 140 mmol/L ; creatinine clearance accord Cockcroft formula &gt; 50 ml/min· Signed informed consent prior begin protocol specific procedures More one line chemotherapy metastatic disease Treatment platinum compound last 3 month randomisation Pregnant lactate woman woman childbearing potential adhere adequate anticonceptive measure Evidence ( ) active invasive malignancy nonmelanoma skin cancer . Clinical evidence CNS metastasis . Symptomatic peripheral neuropathy &gt; grade 2 accord ( NCI CTC , Appendix III ) Definite contraindication use corticosteroids Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen . Concurrent treatment cytotoxic anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Docetaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>relapse SCLC</keyword>
</DOC>